REVIEW ARTIKEL: EVALUASI STRATEGI TAPERING OFF PADA PENGGUNAAN KORTIKOSTEROID JANGKA PANJANG

Michelle Darmawan; Sri Adi Sumiwi

doi:10.24198/farmaka.v23i1.62191

REVIEW ARTIKEL: EVALUASI STRATEGI TAPERING OFF PADA PENGGUNAAN KORTIKOSTEROID JANGKA PANJANG

Michelle Darmawan, Sri Adi Sumiwi

Abstrak

Penggunaan kortikosteroid jangka panjang dalam penatalaksanaan berbagai kondisi medis seringkali diperlukan, namun berhubungan dengan efek samping serius. Oleh karena itu, strategi tapering off menjadi sangat penting untuk diterapkan. Review artikel ini bertujuan untuk mengevaluasi berbagai strategi tapering off kortikosteroid yang telah diteliti serta implikasi klinisnya. Penelusuran literatur dilakukan pada basis data Google Scholar, PubMed, dan Sciencedirect selama 10 tahun terkahir. Studi yang diulas mengungkap bahwa keberhasilan tapering off sangat bergantung pada pendekatan yang dipersonalisasi, dengan mempertimbangkan kondisi klinis, tingkat keparahan penyakit, respons individu terhadap terapi, dan risiko kekambuhan. Temuan menunjukkan bahwa penghentian mendadak pada dosis kortikosteroid yang tinggi dapat memicu relapse dan perburukan kondisi, sementara penggunaan agen steroid-sparing sebagai bagian dari strategi tapering off dapat mengurangi kebutuhan kortikosteroid dan efek sampingnya. Implikasi klinis dari review ini menekankan pentingnya pemantauan ketat dan penyesuaian dosis secara bertahap untuk mengoptimalkan outcome terapi dan meningkatkan kualitas hidup pasien.

Teks Lengkap:

PDF

Referensi

Alexandraki KI, Kaltsas GA, Chrousos GP. (2018). Adrenal Suppression, Endotext. South Dartmouth (MA): MDText.com, Inc. Tersedia online di https://www.ncbi.nlm.nih.gov/books/NBK279047/

Baker, E. H. (2020). Is there a safe and effective way to wean patients off long-term glucocorticoids? British Journal of Clinical Pharmacology.

Braca, B., R, D. S., A, S., G, C., A, M., & CV, R. (2025). Adding corticosteroids to galcanezumab in medication overuse headache: A three-arm head-to-head prospective observational cohort study. Revue Neurologique, 181(1), 106–113.

Broder, M. S., Sarsour, K., Chang, E., et al. (2016). Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based analysis. Seminars in Arthritis and Rheumatism, 46(2), 246–252.

Culver, E. L., & Barnes, G. (2017). IgG4-related sclerosing cholangitis. 243–261.

Gatto, M., Zen, M., Cruciani, C., Iaccarino, L., & Doria, A. (2024). Navigating the landscape of SLE treatment: An expert viewpoint on the rationality and limitations of early biologic intervention. 103612.

Judson, M. A., Adelstein, E., Fish, K. M., et al. (2022). Outcomes of prednisone-tapering regimens for cardiac sarcoidosis: A retrospective analysis demonstrating a benefit of infliximab. Respiratory Medicine, 203, 107004.

Oni, L., Thorbinson, C., & Beresford, M. W. (2015). Juvenile-onset systemic lupus erythematosus: How to diagnose and manage. 25(12), 555–560.

Priya, G., Laway, B. A., Ayyagari, M., Gupta, M., Bhat, G. H. K., & Dutta, D. (2024). The Glucocorticoid Taper: A Primer for the Clinicians. Indian Journal of Endocrinology and Metabolism, 28(4), 350–362.

Ramamoorthy, S., & Cidlowski, J. A. (2016). Corticosteroids-Mechanisms of Action in Health and Disease. Rheumatic Diseases Clinics of North America, 42(1), 15–31.

Rice, J. B., White, A. G., Scarpati, L. M., Wan, G., & Nelson, W. W. (2017). Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. Clinical Therapeutics, 39(11), 2216–2229. https://doi.org/10.1016/j.clinthera.2017.09.011

Rongvaux-Gaïda, D., Dupuis, M., Poupon, J., et al. (2022). High Response Rate and Corticosteroid Sparing with Arsenic Trioxide-Based First-Line Therapy in Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 28(10), 679.e1-679.e11.

Sagdeo, A., Askari, A., Dixey, J., Morrissey, H., & Ball, P. A. (2019). Steroid-Sparing Agents in Giant Cell Arteritis. Vol. 13, 61-71.

Samuel, S., Nguyen, T., & Choi, H. A. (2017). Pharmacologic Characteristics of Corticosteroids. Journal of Neurocritical Care, 10(2), 53–59.

Sekar, A., Gandhi, P., Sheldon, V., Reddy, A., & Campbell, R. (2023). A Case of Maintenance Prednisone in ANCA Glomerulonephritis. 3(1), 5.

Sher, L. D., Wechsler, M. E., Rabe, K. F., et al. (2022). Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial. Chest, 162(1), 46–55.

Strehl, C., Bijlsma, J. W. J., de Wit, M., Boers, M., et al. (2016). Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: Viewpoints from an EULAR task force. Annals of the Rheumatic Diseases, 75(6), 952–957.

Xia, X., & Lv, L. (2022). Cerebral amyloid angiopathy-related inflammation with posterior reversible encephalopathy syndrome-like presentation: A case report. BMC Neurology, 22(1), 449.

Yamamura, T., Araki, M., Fujihara, K., et al. (2022). Exploring steroid tapering in patients with neuromyelitis optica spectrum disorder treated with satralizumab in SAkuraSky: A case series. Multiple Sclerosis and Related Disorders, 61, 103772.

Yasir M, Goyal A, Sonthalia S. (2023). Corticosteroid Adverse Effects. Treasure Island (FL): StatPearls Publishing. Tersedia online di https://www.ncbi.nlm.nih.gov/books/NBK531462/

DOI: https://doi.org/10.24198/farmaka.v23i1.62191

DOI (PDF): https://doi.org/10.24198/farmaka.v23i1.62191.g26312